BioNTech Cash vs Total Current Liabilities Analysis

0A3M Stock

119.55 0.38 0.32%

BioNTech financial indicator trend analysis is way more than just evaluating BioNTech SE prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioNTech SE is a good investment. Please check the relationship between BioNTech Cash and its Total Current Liabilities accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Cash vs Total Current Liabilities

Cash vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioNTech SE Cash account and Total Current Liabilities. At this time, the significance of the direction appears to have very strong relationship.

The correlation between BioNTech's Cash and Total Current Liabilities is 0.89. Overlapping area represents the amount of variation of Cash that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of BioNTech SE, assuming nothing else is changed. The correlation between historical values of BioNTech's Cash and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash of BioNTech SE are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Cash i.e., BioNTech's Cash and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.89

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Cash

Cash refers to the most liquid asset of BioNTech SE, which is listed under current asset account on BioNTech SE balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from BioNTech customers. The amounts must be unrestricted with restricted cash listed in a different BioNTech account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Total Current Liabilities

Total Current Liabilities is an item on BioNTech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioNTech SE are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from BioNTech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioNTech SE current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Selling General Administrative is likely to gain to about 124.9 M in 2024, despite the fact that Tax Provision is likely to grow to (137.7 M).

	2019	2020	2023	2024 (projected)
Gross Profit	91.2M	423.0M	486.4M	510.8M
Total Revenue	108.6M	482.3M	554.7M	582.4M

Gross Profit Total Revenue

BioNTech fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Cash And Short Term Investments	Net Receivables	Good Will	Short Term Investments	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Long Term Debt	Treasury Stock	Deferred Long Term Liab
Total Assets		0.9	0.9	1.0	0.29	0.9	0.87	0.93	1.0	0.88	1.0	0.88	0.99	0.99	0.9	0.98	0.99	0.86	0.9	0.93	0.93	0.97	1.0	1.0	0.49	-0.62
Other Current Liab	0.9		1.0	0.89	0.58	1.0	1.0	0.97	0.89	0.83	0.9	1.0	0.91	0.91	1.0	0.95	0.91	0.76	1.0	0.84	0.8	0.98	0.9	0.91	0.31	-0.69
Total Current Liabilities	0.9	1.0		0.89	0.58	1.0	1.0	0.98	0.89	0.83	0.9	1.0	0.91	0.91	1.0	0.95	0.91	0.76	1.0	0.84	0.8	0.98	0.9	0.91	0.31	-0.69
Total Stockholder Equity	1.0	0.89	0.89		0.24	0.89	0.85	0.9	1.0	0.86	1.0	0.86	0.98	0.98	0.88	0.97	1.0	0.84	0.88	0.93	0.95	0.96	0.99	0.98	0.5	-0.59
Other Liab	0.29	0.58	0.58	0.24		0.58	0.62	0.55	0.25	0.3	0.26	0.61	0.33	0.34	0.58	0.41	0.27	0.49	0.59	0.43	0.2	0.45	0.27	0.32	0.12	-0.18
Net Tangible Assets	0.9	1.0	1.0	0.89	0.58		1.0	0.97	0.89	0.82	0.89	1.0	0.9	0.9	1.0	0.94	0.91	0.75	1.0	0.83	0.81	0.98	0.89	0.9	0.3	-0.68
Retained Earnings	0.87	1.0	1.0	0.85	0.62	1.0		0.96	0.86	0.8	0.86	1.0	0.87	0.87	1.0	0.92	0.88	0.72	1.0	0.8	0.77	0.96	0.86	0.87	0.27	-0.68
Accounts Payable	0.93	0.97	0.98	0.9	0.55	0.97	0.96		0.91	0.87	0.92	0.96	0.95	0.95	0.97	0.98	0.92	0.82	0.97	0.87	0.79	0.98	0.93	0.95	0.37	-0.69
Cash	1.0	0.89	0.89	1.0	0.25	0.89	0.86	0.91		0.87	1.0	0.87	0.98	0.98	0.89	0.97	1.0	0.84	0.89	0.93	0.94	0.97	0.99	0.99	0.49	-0.61
Other Assets	0.88	0.83	0.83	0.86	0.3	0.82	0.8	0.87	0.87		0.87	0.81	0.88	0.88	0.83	0.89	0.87	0.72	0.82	0.81	0.78	0.88	0.88	0.88	0.22	-0.74
Cash And Short Term Investments	1.0	0.9	0.9	1.0	0.26	0.89	0.86	0.92	1.0	0.87		0.87	0.99	0.99	0.89	0.98	1.0	0.85	0.89	0.93	0.94	0.97	0.99	0.99	0.49	-0.61
Net Receivables	0.88	1.0	1.0	0.86	0.61	1.0	1.0	0.96	0.87	0.81	0.87		0.88	0.88	1.0	0.93	0.89	0.73	1.0	0.81	0.78	0.96	0.87	0.88	0.28	-0.69
Good Will	0.99	0.91	0.91	0.98	0.33	0.9	0.87	0.95	0.98	0.88	0.99	0.88		1.0	0.9	0.99	0.98	0.88	0.9	0.93	0.89	0.97	0.99	1.0	0.51	-0.61
Short Term Investments	0.99	0.91	0.91	0.98	0.34	0.9	0.87	0.95	0.98	0.88	0.99	0.88	1.0		0.9	0.99	0.98	0.88	0.9	0.93	0.89	0.97	0.99	1.0	0.52	-0.6
Inventory	0.9	1.0	1.0	0.88	0.58	1.0	1.0	0.97	0.89	0.83	0.89	1.0	0.9	0.9		0.94	0.91	0.75	1.0	0.84	0.8	0.98	0.9	0.9	0.31	-0.68
Other Current Assets	0.98	0.95	0.95	0.97	0.41	0.94	0.92	0.98	0.97	0.89	0.98	0.93	0.99	0.99	0.94		0.97	0.87	0.94	0.92	0.87	0.99	0.98	0.99	0.47	-0.64
Other Stockholder Equity	0.99	0.91	0.91	1.0	0.27	0.91	0.88	0.92	1.0	0.87	1.0	0.89	0.98	0.98	0.91	0.97		0.83	0.91	0.92	0.95	0.97	0.99	0.98	0.48	-0.61
Total Liab	0.86	0.76	0.76	0.84	0.49	0.75	0.72	0.82	0.84	0.72	0.85	0.73	0.88	0.88	0.75	0.87	0.83		0.75	0.96	0.82	0.82	0.86	0.88	0.71	-0.25
Total Current Assets	0.9	1.0	1.0	0.88	0.59	1.0	1.0	0.97	0.89	0.82	0.89	1.0	0.9	0.9	1.0	0.94	0.91	0.75		0.83	0.8	0.97	0.89	0.9	0.3	-0.69
Intangible Assets	0.93	0.84	0.84	0.93	0.43	0.83	0.8	0.87	0.93	0.81	0.93	0.81	0.93	0.93	0.84	0.92	0.92	0.96	0.83		0.93	0.9	0.93	0.93	0.56	-0.44
Common Stock	0.93	0.8	0.8	0.95	0.2	0.81	0.77	0.79	0.94	0.78	0.94	0.78	0.89	0.89	0.8	0.87	0.95	0.82	0.8	0.93		0.88	0.93	0.9	0.48	-0.47
Property Plant Equipment	0.97	0.98	0.98	0.96	0.45	0.98	0.96	0.98	0.97	0.88	0.97	0.96	0.97	0.97	0.98	0.99	0.97	0.82	0.97	0.9	0.88		0.97	0.97	0.4	-0.68
Short Long Term Debt Total	1.0	0.9	0.9	0.99	0.27	0.89	0.86	0.93	0.99	0.88	0.99	0.87	0.99	0.99	0.9	0.98	0.99	0.86	0.89	0.93	0.93	0.97		0.99	0.51	-0.6
Long Term Debt	1.0	0.91	0.91	0.98	0.32	0.9	0.87	0.95	0.99	0.88	0.99	0.88	1.0	1.0	0.9	0.99	0.98	0.88	0.9	0.93	0.9	0.97	0.99		0.51	-0.61
Treasury Stock	0.49	0.31	0.31	0.5	0.12	0.3	0.27	0.37	0.49	0.22	0.49	0.28	0.51	0.52	0.31	0.47	0.48	0.71	0.3	0.56	0.48	0.4	0.51	0.51		0.35
Deferred Long Term Liab	-0.62	-0.69	-0.69	-0.59	-0.18	-0.68	-0.68	-0.69	-0.61	-0.74	-0.61	-0.69	-0.61	-0.6	-0.68	-0.64	-0.61	-0.25	-0.69	-0.44	-0.47	-0.68	-0.6	-0.61	0.35

Click cells to compare fundamentals

BioNTech Account Relationship Matchups

BioNTech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Other Current Liab	77.0M	105.6M	494.6M	3.2B	3.7B	3.9B
Total Current Liabilities	126.1M	138.1M	606M	3.5B	4.0B	4.2B
Other Liab	205.6M	97.1M	109.8M	283.9M	326.5M	200.3M
Net Tangible Assets	179.6M	406.5M	1.2B	11.7B	13.5B	14.1B
Retained Earnings	(245.8M)	(424.8M)	(409.6M)	9.9B	11.4B	11.9B
Accounts Payable	41.7M	20.5M	102.3M	160M	184M	193.2M
Other Assets	2.4M	168.2M	22.2M	249.2M	286.6M	300.9M
Net Receivables	28.7M	20.2M	166.4M	12.4B	14.2B	15.0B
Inventory	5.9M	12.1M	64.1M	502.5M	577.9M	606.8M
Other Current Assets	2.5M	7.0M	89M	113.4M	130.4M	136.9M
Other Stockholder Equity	318.6M	691.5M	1.5B	1.8B	2.0B	2.1B
Total Current Assets	449.0M	560.2M	1.7B	15.1B	17.3B	18.2B
Property Plant Equipment	116.0M	148.1M	326M	520.4M	598.5M	628.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

BioNTech Cash vs Total Current Liabilities Analysis

Cash vs Total Current Liabilities

Cash vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Cash

Total Current Liabilities

BioNTech fundamental ratios Correlations

BioNTech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNTech fundamental ratios Accounts

Also Currently Popular

Additional Tools for BioNTech Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Short Long Term Debt Total	+ 1.0	Total Assets
Long Term Debt	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Other Current Liab

Deferred Long Term Liab	- 0.74	Other Assets
Deferred Long Term Liab	- 0.69	Total Current Assets
Deferred Long Term Liab	- 0.69	Net Receivables
Deferred Long Term Liab	- 0.69	Accounts Payable
Deferred Long Term Liab	- 0.69	Total Current Liabilities
Deferred Long Term Liab	- 0.69	Other Current Liab